T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: An effective in vivo antitumor strategy

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 180-183

  Porter, Lewis E ^a   Nelson, Heidi ^a   Gecim, I Ethem ^a   Rice, David C ^a   Thibault, Claude ^a   Chapoval, Andrei I ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bispecific antibodies; Micrometastatic; T cell activation; Tumor immunity

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CANCER ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY CD3; STAPHYLOCOCCUS ENTEROTOXIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOTOXICITY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ENTEROTOXINS; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; T-LYMPHOCYTES;

EID: 0030727184     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050427     Document Type: Article

References (21)

1. Chapoval AI, Nelson H, Thibault C (1995) Ami-CD3 x anti-tumor F(ab′)2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes. J Immunol 155: 1296
2. Di Renzo L, Yefenof E, Klein E (1991) The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18). Eur J Immunol 21: 1755
3. Duan X, Ackerly M, Vivier E, Anderson P (1994) Evidence for involvement of beta-glucan-binding cell surface lectins in human natural killer cell function. Cell Immunol 157: 393
4. Economou JS, Belldegrun AS, Glaspy J, Toloza EM, Figlin R, Hobbs J, Meldon N, Kaboo R, Tso CL, Miller A, Lau R, McBride W, Moen RC (1996) In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J Clin Invest 97: 515
5. Gallin EK, Green SW, Patchen ML (1992) Comparative effects of particulate and soluble glucan on macrophages of C3H/HeN and C3H/HeJ mice. Int J Immunopharmacol 14: 173
6. Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ (1992) A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma [published erratum appears in J Clin Oncol (1992) 10:1822]. J Clin Oncol 10:1124
7. Karpovsky B, Titus JA, Stephany DA, Segal DM (1984) Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J Exp Med 160: 1686
8. Nelson H, Ramsey PS, Kerr LA, McKean DJ, Donohue JH (1990) Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft. J Immunol 145: 3507
9. Nelson H, Ramsey PS, McKean DJ, Dozois RR, Donohue JH (1991) Anti- tumor X anti-lymphocyte heteroconjugates augment colon tumor cell lysis in vitro and prevent tumor growth in vivo. Dis Col Rec 34: 140
10. Newell KA, Ellenhorn JD, Bruce DS, Bluestone JA (1991) In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. Proc Natl Acad of Sci USA 88: 1074
11. Penna C, Dean PA, Nelson H (1994) Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res 54: 2738
12. Penna C, Dean PA, Nelson H (1996) Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody. Int J Cancer 65: 377
13. Perez P, Titus JA, Lotze MT, Cuttitta F, Longo DL, Groves ES, Rabin H, Durda PJ, Segal DM (1986) Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J Immunol 137: 2069
14. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889
15. Sherwood ER, Williams DL, McNamee RB, Jones EL, Browder IW, Di Luzio NR (1987) Enhancement of interleukin-1 and interleukin-2 production by soluble glucan. Int J Immunopharmcol 9: 261
16. Thibault C, Nelson H, Chapoval AI (1996) Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab′)2 bispecific antibodies. Int J Cancer 67: 232
17. Topalian SL, Muul LM, Solomon D, Rosenberg SA (1987) Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102:127
18. Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H (1982) Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med 155: 557
19. Uyttenhove C, Maryanski J, Boon T (1983) Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157: 1040
20. Ward PL, Koeppen HK, Hurteau T, Rowley DA, Schreiber H (1990) Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res 50: 3851
21. Yang SC, Fry KD, Grimm EA, Roth JA (1991) Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy. J Immunother 10: 326